Prnewswire·2026-02-11 14:00Core Viewpoint - A securities class action has been filed against Vistagen Therapeutics, Inc. for alleged violations of federal securities laws, specifically related to misleading statements and omissions during a defined period [1] Legal Claims - The complaint asserts claims under Section 10(b) and Section 20(a) of the Securities Exchange Act of 1934, along with Rule 10b-5, which prohibits materially false or misleading statements in securities transactions [1] - Section 20(a) holds controlling persons liable for the conduct of those primarily liable [1] Class Definition - The class includes all individuals and entities that purchased Vistagen common stock from April 1, 2024, to December 16, 2025, and suffered damages upon the revelation of alleged corrective disclosures [1] - Exclusions from the class include defendants, company officers and directors, their immediate family members, and legal representatives [1] PSLRA Procedures - Under the Private Securities Litigation Reform Act of 1995, class members can seek to serve as lead plaintiff by filing a motion with the court by March 16, 2026 [1] - The lead plaintiff will manage the litigation on behalf of the class, and participation in any recovery is not affected by the decision to serve as lead plaintiff [1] About the Law Firm - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [1] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years [1]